Stelo by Dexcam

Subject: Urgent Consumer Feedback: Missing Clarity on Pre-Sales Marketing for Non-Insulin Users (Stelo)

To the Product Marketing & Executive Leadership Teams at Dexcom,

As an over-the-counter customer utilizing the Dexcom Stelo Glucose Biosensor System, I am writing to strongly urge your marketing division to update the Stelo pre-sales and landing pages. Currently, marketing materials emphasize a generalized "93% accuracy" metric. However, they do not transparently illustrate the functional real-world impact of the permitted ±20% regulatory variance window on healthy, non-diabetic consumers.

With a documented HbA1c baseline of 4.9, I track my metabolic health seeking tight point-by-point precision. Instead, I discovered that under your current FDA clearance window (510(k) number K234070), a completely stable, healthy fasting blood sugar of 97 mg/dL can display on the app as 116.4 mg/dL—mimicking prediabetes. Similarly, a completely normal post-meal value of 114 mg/dL can be magnified by a standard sensor drift to display as an alarming 137 mg/dL.

When health-conscious buyers purchase an over-the-counter tracker, they expect single-point fidelity. Experiencing shifts this wide without upfront warning causes undue distress and panic. I urge Dexcom to include real-world scenario tables—similar to the the fasting and post-meal numbers noted above—directly on your primary selling pages. Transparency regarding the interstitial fluid lag and the ±20% window will manage consumer expectations, mitigate tech-support confusion, and build a more informed community.